LabRoots is pleased to announce the inauguration of the Immuno-Oncology Virtual Event taking place on June 2, 2021. Immuno-Oncology is considered by some to be one of the most promising areas of research in the world of anti-cancer therapeutics. Learn from our experts how immunotherapies can work alone, together, or in combination with other treatments to fight cancer.
This year's event includes the following tracks and topics:
New Advancements in Immuno-Oncology
Emerging Targets for Immuno-Oncology Therapy
Advancing Cancer Immunotherapies to the Clinic
Recent breakthroughs in immuno-oncology research translate into a paradigm shift with regards to attacking advancing cancer. The benefits of immuno-oncology have resulted in long-lasting tumor regression where surgery, radiotherapy, chemotherapy, and targeted therapy proved less effective.
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
Like the 2020 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2021 Immuno-Oncology Virtual Event. Submission is free. Submit your abstract here.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.
Use #LRimmuno to follow the conversation!
Dr. Burrack obtained B.S. in Biology at the University of Wisconsin and a M.S. in Physiology at the University of Wisconsin-La Crosse. He went on to complete his PhD in Immunology at the University of Colorado – Anschutz Medical Campus. Family history of both type 1 diabetes and pancreatic cancer have greatly influenced Dr. Burrack’s scientific interests and research experiences. During graduate school, Dr. Burrack studied autoimmune diabetes recurrence and transplant recognition in a mouse model of type 1 diabetes in the laboratory of Ronald Gill. He then pursued post-doctoral at the University of Minnesota where he defined antigens that are recognized by alloreactive T cells direct transplant recognition. He also investigated how pancreatic beta cells respond to inflammation in the context of diabetes. With this background and specific interest in pancreatic diseases, he next joined the laboratory of Dr. Ingunn Stromnes at the University of Minnesota in the Center for Immunology. Over the past 3 years, he has developed novel mouse models of pancreatic cancer to interrogate the fate and functionality of tumor-specific T cells as well as mechanisms of immunotherapy resistance in the highly lethal disease, pancreatic cancer. This work has led to two first author publications in Cell Reports and Journal of Immunology. With these new models in hand, he is identifying novel strategies to enhance anti-tumor T cells in vivo to support pancreatic cancer eradication to inform clinical translation for pancreatic cancer patient treatment.
Leah Schmidt, PhD, is a postdoctoral fellow in the laboratory of Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center, and an AACR-AstraZeneca Immuno-oncology Research Fellow. Her research is focused on utilizing preclinical models for refining and improving engineered T cell therapies against solid tumors, including lung and pancreatic cancers. Prior to Fred Hutch, Dr. Schmidt completed her PhD thesis in the laboratory of Dr. Tyler Jacks at the Massachusetts Institute of Technology, where she studied the roles of natural killer cells in shaping anti-tumor immune responses in genetically engineered preclinical models. Her overarching scientific interest is uncovering strategies for improving patient outcomes by leveraging the immune system against human disease.
Dr. Peter Sullivan obtained his B.A. in Biology and Chemistry from Lake Forest College and his Ph.D. from Cornell University, studying the molecular biology underlaying the neurodegenerative diseases ALS and FTLD. After obtaining his Ph.D., he moved into CD8 T cell biology to better understand how the immune system functions in health and disease with the goal of applying this knowledge to novel cellular therapies. He is currently a post-doctoral fellow working with Dr. Rimas Orentas at Seattle Children’s Research Institute. His research is focused on optimizing CAR T cell therapy for the treatment of pediatric solid tumors. Dr. Sullivan is excited to continue working in the emerging field of engineered cellular therapy.
Visiopharm® is a world leader in Augmented Pathology™ solutions; that comprise precision pathology and high-throughput pathology for tissue-diagnostics and research. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and ...See more See less
Sino Biological, Inc. is a global leader in manufacturing affordable, high-quality reagents, including recombinant proteins, antibodies and cDNA clones-all in-house. We provide a one-stop shop for researchers and pharmaceutical companies around the world, helping our customers ...See more See less
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The ...See more See less
For more than 30 years, GoldBio has been committed to researchers around the world. We know providing quality reagents to scientists leads to discoveries that benefit all. That is why we provide our customers with only the best chemicals, tested in GoldBio labs to ensure the ...See more See less
GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a ...See more See less
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic ...See more See less
OriGene Technologies was founded as a research tool company focused on the creation of the large commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based ...See more See less
Millipore Sigma is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis ...See more See less
BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Guided by our award-winning entrepreneurial leadership team, we ...See more See less
Miltenyi Biotec delivers solutions that advance biomedical research and cellular therapy. As the SARS-CoV-2 pandemic continues to take its toll around the world, Miltenyi Biotec stands committed to helping our customers navigate through this challenging time. With over 30 years ...See more See less
PerkinElmer is working closely with laboratories around the world to deliver the nucleic acid isolation, automation, real-time PCR, antibody testing, and NGS library preparation solutions they need to rapidly respond to the SARS-CoV-2 challenges both today and tomorrow. To ...See more See less
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
Tullia C. Bruno, PhD, is an Assistant Professor in the Department of Immunology at the University of Pittsburgh and a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. She obtained her Ph.D ...See more See less
Dr. Shannon Oda earned a Ph.D. in Immunology from the University of Colorado Anschutz Medical Campus and completed her postdoctoral training with Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center. She has received several awards, including the Evergreen Fund ...See more See less
Dr. Sater is a translational physician scientist (hematologist/oncologist) with special interest in immune therapy of cancer. He leads the Genitourinary Malignancies Branch efforts at understanding the role of cancer immunotherapy on the tumor (immune and non-immune) ...See more See less
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events
Research And Development
Labroots Registration (Also interested in)60%
WAVE Newsletter Promotion2%
Social Media Promotions1%
Medical Laboratory Technician6%
Clinical Laboratory Scientist2%
Life Science Company3%